Exclusive Summary

• Bromhexine Hydrochloride Injection is a globally recognized mucolytic, with stable demand, especially in regions with high incidence of respiratory diseases.
• The product has passed China's consistency evaluation and is self-produced, offering reliable quality and cost competitiveness for global registration and market expansion.
• Included in the WHO Essential Medicines List and widely recommended by guidelines, it holds high clinical status and penetration, securing reimbursement approval in many countries.
• The company's advantages in quality and cost will attract overseas partners seeking high-quality and reliable supply channels in a competitive generics market.
• The injectable formulation ensures rapid onset of action, providing immediate treatment for critical patients and meeting the clinical needs of healthcare institutions.

Asset Materials

Contact Us for Full Materials